Lumira Ventures — 2023 Investments

3 investments dated 2023 · listed companies and verified rows first · show all

Cadence Neurosciencecadenceneuro.com inFeb 2023 · $26M✓ verified

Cadence develops a neuromodulation system intended to be a more effective, less invasive treatment for people living with drug-refractory epilepsy.

BiotechDigital HealthHealthtechMedical DevicesSammamish, US

Kent Leyde(Executive Officer, Director, Promoter)inWarren Douglas Sheffield(Executive Officer, Director, Promoter)

Board seatGerry Brunk· per SEC Form D

Co-investorsJAZZ Venture Partners Angelini Ventures F-Prime Capital Iaso Ventures Mayo Clinic Ventures

Antiva Biosciencesantivabio.com inApr 2023 · $53M

Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry.

BiotechFemTechHealthtechMedical DevicesRedwood City, US

Karl Y. Hostetler(Executive Officer, Director)inGail Maderis(Director)inKristine Ball(President & CEO)inElaine Chien(Executive Officer)inSarah Walter(Executive Officer)inRaju Gadiraju(Executive Officer)in

Co-investorsAdjuvant Capital Avestria Ventures Brace Pharma Canaan Partners Gaingels GV (Google Ventures)+6 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

GenEp

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.